Related Experiment Video
Updated: Jun 10, 2025
14:03
High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
Published on: March 24, 2023
1.8K
Drug-induced myocarditis: a real-world pharmacovigilance study using the FDA adverse event reporting system database
Yunxiang Zhong1, Zhiping Li1, Jinyi Tao2
1Department of Pharmacy, Dongguan Binhaiwan Center Hospital, Dongguan, China.
Expert Opinion on Drug Safety
|October 14, 2024
Summary
Drug-induced myocarditis is a serious heart condition. This study identified several drugs, including clozapine and nivolumab, linked to myocarditis risk using FDA data, highlighting the need for monitoring.
Area of Science:
- Cardiology
- Pharmacovigilance
- Drug Safety
Background:
- Myocarditis, a rare but severe inflammation of the heart muscle, can be triggered by various medications.
- Evaluating drug-induced myocarditis is critical for patient safety and effective treatment strategies.
Purpose of the Study:
- To comprehensively assess the risk of drug-induced myocarditis.
- To identify specific drugs associated with myocarditis using a large adverse event database.
Main Methods:
- Utilized the FDA Adverse Event Reporting System (FAERS) database from Q1 2004 to Q4 2023.
- Calculated Reporting Odds Ratios (ROR) and Proportional Reporting Ratios (PRR) to detect drug-associated myocarditis signals.
Main Results:
- Identified 8,212 reports of myocarditis.
- Top implicated drugs include clozapine, nivolumab, and pembrolizumab.
- Disproportionality analysis revealed significant signals for drugs like mesalazine, cemiplimab, and clozapine.
Conclusions:
- Findings suggest a potential risk of drug-induced myocarditis with several medications.
- Emphasizes the importance of monitoring patients for myocarditis symptoms, especially those on high-risk drugs.
- Further research is needed to confirm causality and identify specific risk factors.
Related Concept Videos
01:19Pharmacovigilance
783
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
783
01:14Myocarditis III: Medical Management
2
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2
01:25Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
01:22Myocarditis IV: Nursing Management
2
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
2
01:27Myocarditis II: Clinical features and Diagnostic Tests
2
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
2
01:21Myocarditis I: Introduction
2
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
2